NPS Announces Extension of R&D Collaboration With AstraZeneca
10-Feb-2006
Under the terms of the extended agreement, the companies will continue their research collaboration for a minimum of three years with options to extend for an additional two years. AstraZeneca is presently engaged in Phase 1 clinical development activities with an mGluR active molecule discovered together with NPS.
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.